| Characteristic | Finding | Evidence Level | Key Citations |
|---|---|---|---|
| Protein family/classification | DNAJC25 (UniProt Q9H1X3) is the human **DnaJ/Hsp40 J-domain protein** “DnaJ homolog subfamily C member 25,” containing the conserved **J/DnaJ domain** typical of Hsp70 co-chaperones. Its family assignment is strong, but functional specialization within the DNAJC subgroup remains unclear. | **High for family assignment; low for protein-specific specialization** | Guo et al., 2023, *Cancers*, doi:10.3390/cancers15215203; Kampinga et al., 2019, *Cell Stress Chaperones*, doi:10.1007/s12192-018-0948-4; Liu et al., 2020, *Protein Science*, doi:10.1002/pro.3725 |
| Primary molecular function | No dedicated biochemical study defines a unique client or reaction for DNAJC25. Based on conserved J-domain biology, the most likely primary function is as an **Hsp70 co-chaperone** that helps recruit/select client proteins and stimulate Hsp70 ATPase activity in protein quality control. This remains **inferred**, not directly demonstrated for DNAJC25 itself. | **Moderate for family-level inference; low for DNAJC25-specific proof** | Kityk et al., 2018, *Molecular Cell*, doi:10.1016/j.molcel.2017.12.003; Zhang et al., 2023, *Trends in Cell Biology*, doi:10.1016/j.tcb.2022.05.004; Liu et al., 2020, *Protein Science*, doi:10.1002/pro.3725 |
| Subcellular localization | Direct localization data for human DNAJC25 were not identified in the retrieved literature. Current understanding is therefore **uncertain**; a **likely intracellular/cytosolic** role is inferred from general J-domain protein behavior, but this should be treated cautiously until experimentally validated. | **Low** | Guo et al., 2023, *Cancers*, doi:10.3390/cancers15215203; Kampinga et al., 2019, *Cell Stress Chaperones*, doi:10.1007/s12192-018-0948-4 |
| Known interactions (especially RNF149) | The clearest specific interaction in recent literature is with **RNF149**, an E3 ubiquitin ligase. Guo et al. reported DNAJC25 as a **novel RNF149 substrate** and described RNF149-dependent **UPS/proteasome-mediated degradation** of DNAJC25 in hepatocellular carcinoma-related work; Wu et al. later cited this relationship in an innate immunity study. DNAJC25 also appears in broader Hsp70-network screens, but without deep mechanistic follow-up. | **Moderate** | Guo et al., 2023, *Cancers*, doi:10.3390/cancers15215203; Wu et al., 2025, *PLOS Pathogens*, doi:10.1371/journal.ppat.1013051; Barbieri et al., 2025, *bioRxiv*, doi:10.1101/2025.05.10.653282 |
| Role in cancer/disease | Evidence suggests DNAJC25 may have a **context-dependent tumor-related role**, but this is not firmly established mechanistically. In HCC, its degradation by RNF149 was linked to tumor-promoting effects of RNF149, implying DNAJC25 could act in a **tumor-suppressive or growth-restraining direction** in that context. Broader cancer analyses place DNAJC25 among HSP family members associated with proliferation-related patterns, but these are mostly correlative. | **Low to moderate** | Guo et al., 2023, *Cancers*, doi:10.3390/cancers15215203; Zhang et al., 2020, *Genome Medicine*, doi:10.1186/s13073-020-00795-6; Chatterjee and Burns, 2017, *IJMS*, doi:10.3390/ijms18091978 |
| Expression regulation | DNAJC25 expression appears **stress-responsive/cancer-context dependent** rather than uniformly characterized. Rauschner et al. reported **downregulation of Dnajc25 under acidic tumor-like conditions** in rat tumor models. Pan-cancer and breast cancer HSP transcriptomic studies include DNAJC25 among heterogeneously regulated HSP genes, but regulation in normal human tissues remains poorly defined. | **Low** | Rauschner et al., 2021, *J Exp Clin Cancer Res*, doi:10.1186/s13046-020-01815-4; Zoppino et al., 2018, *BMC Cancer*, doi:10.1186/s12885-018-4621-1; Zhang et al., 2020, *Genome Medicine*, doi:10.1186/s13073-020-00795-6 |
| Current research status | DNAJC25 is a **poorly characterized human gene/protein**. Recent literature (2023-2025) mentions it mainly as an RNF149 substrate or as one member of larger Hsp70/J-domain screens; no dedicated study yet defines its endogenous clients, precise localization, pathway placement, or disease mechanism. The strongest current conclusion is that its **J-domain strongly supports a co-chaperone identity**, while its **specific biology remains largely unresolved**. | **High confidence that the field is sparse; low confidence for detailed function** | Guo et al., 2023, *Cancers*, doi:10.3390/cancers15215203; Barbieri et al., 2025, *bioRxiv*, doi:10.1101/2025.05.10.653282; Kampinga et al., 2019, *Cell Stress Chaperones*, doi:10.1007/s12192-018-0948-4 |


*Table: This table summarizes what is currently known and unknown about human DNAJC25, emphasizing the distinction between strong family-level inference and limited DNAJC25-specific experimental evidence. It is useful for quickly identifying where the literature is solid, provisional, or sparse.*